Joyce A. O’Shaughnessy, MD
Novel and emerging agents are creating exciting new options for patients with hormone receptor (HR)–positive metastatic breast cancer (MBC), resulting in the need to consider how best to introduce and sequence these agents into the treatment timeline, experts say.
Incorporating CDK4/6 Inhibitors
The FDA has approved 3 oral CDK4/6 inhibitors for HR-positive, HER2-negative MBC: palbociclib (Ibrance),4
and abemaciclib (Verzenio).6
Although the CDK4/6 inhibitors have slightly different indications, all are typically administered with an aromatase inhibitor (AI) in the first-line setting or with fulvestrant (Faslodex), an injectable selective ER modulator, in the second-line setting. Ribociclib is the only CDK4/6 inhibitor indicated for first-line therapy in pre- or perimenopausal women in addition to postmenopausal women.5
... to read the full story